In adults with polycystic ovarian syndrome and a body mass index of 25 kg/m² or greater, Metformin is an initial treatment targeting metabolic outcomes such as glucose and lipid profiles. When those goals are not achieved, a structured next-line protocol applies.
Adult with PCOS and BMI ≥ 25 kg/m². The priority in this population is improving metabolic parameters including glucose and lipid profiles alongside anthropometric outcomes.
Prior therapy: Metformin alone
Targets not met: Improvement in glucose and lipid profiles
When Metformin alone has failed to achieve these metabolic targets, the following protocol defines the next step.
The next step combines anti-obesity pharmacotherapy with active lifestyle intervention. The full protocol details which class of agent is appropriate and how treatment is escalated — that information is available via the link below.
DOI: 10.1016/j.fertnstert.2023.07.025
Metformin alone should be considered in adults with PCOS and a BMI ≥ 25 kg/m² for anthropometric, and metabolic outcomes including insulin resistance, glucose, and lipid profiles.
Anti-obesity medications including liraglutide, semaglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists and orlistat, could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines.
Gradual dose escalation for GLP-1 receptor agonists is recommended to reduce gastrointestinal adverse effects.
View source ↗